Nilotinib

Phase 3Terminated

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Philadelphia Positive (Ph+) Chronic Myeloid Leukemia

Conditions

Philadelphia Positive (Ph+) Chronic Myeloid Leukemia

Trial Timeline

Dec 17, 2015 → Oct 31, 2016

NCT ID

NCT02115386

About Nilotinib

Nilotinib is a phase 3 stage product being developed by Novartis for Philadelphia Positive (Ph+) Chronic Myeloid Leukemia. The current trial status is terminated. This product is registered under clinical trial identifier NCT02115386. Target conditions include Philadelphia Positive (Ph+) Chronic Myeloid Leukemia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04559555	Pre-clinical	Completed	—	—	Acute Lymphoblastic Leukemia (ALL)
NCT04498871	Pre-clinical	Completed	—	—	Hypereosinophilic Syndrome (HES)
NCT04518644	Pre-clinical	Completed	—	—	Chronic Myelogenous Leukemia (CML)
NCT02774512	Phase 1	Withdrawn	May 1, 2016	Nov 1, 2017	Colon Cancer
NCT02546674	Approved	Completed	Feb 18, 2016	Mar 25, 2021	Chronic Myeloid Leukemia
NCT02115386	Phase 3	Terminated	Dec 17, 2015	Oct 31, 2016	Philadelphia Positive (Ph+) Chronic Myeloid Leukemia
NCT02353728	Phase 2	Completed	Jan 1, 2015	Feb 1, 2021	Chronic Myeloid Leukemia
NCT02108951	Phase 3	Terminated	Jul 7, 2014	Aug 10, 2016	Philidelphia Positive Chronic Myeloid Leukaemia
NCT01844765	Phase 2	Completed	Aug 20, 2013	Aug 28, 2020	Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia
NCT01744665	Phase 2	Completed	Aug 12, 2013	Sep 29, 2018	CML
NCT01863745	Phase 2	Completed	Jun 25, 2013	Oct 2, 2023	Gastrointestinal Stromal Tumors
NCT03332511	Approved	Completed	May 6, 2013	Oct 24, 2016	Chronic Myeloid Leukemia, Chronic Phase
NCT01743989	Phase 3	Completed	Apr 15, 2013	Jul 8, 2020	Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
NCT01735955	Approved	Completed	Mar 29, 2013	Jul 7, 2023	Chronic Myelogenous Leukemia (CML)
NCT01698905	Phase 2	Completed	Dec 20, 2012	Jan 29, 2025	Chronic Myeloid Leukemia
NCT01562847	Pre-clinical	UNKNOWN	Jul 1, 2011	Jun 1, 2015	Chronic Myeloid Leukemia
NCT01077544	Phase 1	Completed	Apr 14, 2011	Jul 1, 2015	Chronic Myeloid Leukemia
NCT01254188	Phase 3	Completed	Apr 1, 2011	Nov 1, 2014	Chronic Myeloid Leukemia
NCT01274351	Phase 2	Completed	Jan 25, 2011	Aug 1, 2019	Chronic Myelogenous Leukemia
NCT01270893	Phase 2	Withdrawn	Jan 1, 2011	—	Gastrointestinal Cancer

Competing Products

20 competing products in Philadelphia Positive (Ph+) Chronic Myeloid Leukemia

See all competitors

Product	Company	Stage	Hype Score
Imatinib Mesylate	Novartis	Phase 2	52
Nilotinib	Novartis	Phase 3	77
STI571 400 mg + STI571 600 mg	Novartis	Phase 2	52
Induction Phase + Re-Induction Phase + Post-Remission + Maintenance	Novartis	Phase 2	52
nilotinib	Novartis	Phase 2	52
Asciminib + Nilotinib	Novartis	Phase 3	77
imatinib mesylate	Novartis	Phase 2	52
Blinatumomab + Asciminib	Novartis	Phase 1/2	41
Asciminib	Novartis	Phase 1	33
Asciminib Pediatric formulation group + Asciminib Adult formulation group	Novartis	Phase 1/2	41
Nilotinib + LDE225	Novartis	Phase 1	33
Nilotinib	Novartis	Approved	85
Imatinib + Nilotinib + Bosutinib + Dasatinib + Asciminib	Novartis	Phase 3	77
Asciminib	Novartis	Approved	85
Blinatumomab	Amgen	Phase 2	51
Treatment with blinatumomab given subcutaneously.	Amgen	Phase 2	51
Blinatumomab + Blinatumomab + HyperCVAD	Amgen	Phase 3	76
Blinatumomab + Low-intensity chemotherapy regimen + SOC chemotherapy regimen	Amgen	Phase 3	76
Bosutinib	Pfizer	Phase 1/2	40
Bosutinib + Bosutinib	Pfizer	Phase 1	32

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

NateglinideApproved

TenofovirApproved

FTY720Approved